Management

Stéphane Degove – CEO & CFO

2-4-2

Stéphane has 17 years’ experience in Biotech/Pharma and Strategy. Graduated from ESCP (majoring in Finance), he worked at Sanofi in Finance and was co-founder and CFO of a biotechnology company in cancer and thrombosis, Endotis Pharma. Under his leadership, Endotis Pharma raised € 37 million from international funds and built a portfolio of innovative products developed up to Phase II.

Jean-François Prost, MD – VP R&D and Strategy

2-2-2Jean-François is a Senior Executive of the French and International pharmaceutical industry. Physician specialist in Internal Medicine, Dr. Prost has an experience of 30 years in the industry, having served as Cardiovascular Development Director then Research Director at Servier, R&D Director at Pierre Fabre Medicament and then UCB Pharma, and finally in the last ten years, Scientific and Medical Management at LFB.

Isabelle Tabah-Fisch, MD – Chief Medical Officer

Isabelle is a medical oncologist with over 25 years’ experience in drug development and medical affairs in the pharmaceutical industry. Prior to joining GamaMabs, she held various positions at Sanofi, including VP, Research & Development, VP, Corporate Medical Affairs and VP, Head of the Global Oncology Franchise.  She has been involved in the clinical development and marketing of lead cytotoxic agents (Eloxatin, Taxotere, Jevtana) and monoclonal antibodies (Zaltrap, seribantumab). She also collaborated with a number of European and US-based biotech companies.

Loan Hoang-Sayag, MD – VP Clinical Developpement

 

Loan Hoang-Sayag is a board-certified hematologist-oncologist from Necker-Paris V René Descartes University. Dr. Hoang-Sayag has over 25 years of hematology and oncology experience within the clinical and academic settings and over 18 years of experience leading oncology drug development.

Dr. Hoang-Sayag started her industry career at Roche in the oncology clinical development and medical affairs group.  Following this position, she held roles at Pierre Fabre Oncology and Quintiles where she led oncology development programs and the European Oncology Medical team, respectively.

Most recently, Dr. Hoang-Sayag served as the Chief Medical Officer at Cellectis and at Median Technologies.

Jean-Marc Barret, PhD – Pharmacology Manager

gamamabs1-6Jean-Marc has 20 years’ experience in new entity discovery in oncology, being the former Head of in vitro pharmacology oncology Department of Pierre Fabre.